Abstract
The anti-tumor activity of [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) on the MXT-M-3,2 breast cancer implanted into B6D2F1 mice was not significantly reduced by splenectomy or co-administration of cyclosporine A. Neither did the use of T-lymphocyte-deficient NMRI (nu/nu) mice as hosts substantially influence its anti-tumor effect. Obviously, ...
Abstract
The anti-tumor activity of [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) on the MXT-M-3,2 breast cancer implanted into B6D2F1 mice was not significantly reduced by splenectomy or co-administration of cyclosporine A. Neither did the use of T-lymphocyte-deficient NMRI (nu/nu) mice as hosts substantially influence its anti-tumor effect. Obviously, [meso-1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) does not act by an enhancement of the specific immune defense.
Altmetric